NCT02979015 - A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

November 27, 2017

Study Completion Date

November 27, 2017

Conditions

Hypercholesterolemia

Interventions

DRUG

alirocumab SAR236553 (REGN727)

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"

DRUG

placebo

"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"

Trial Locations (1)

Investigational Site Number 156001, Beijing